Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand

Journal of Immunology

Volumn 172, Issue 10, 2004, Pages 5948-5956

  Madrenas, Joaquín ^a   Chau, Luan A ^a   Teft, Wendy A ^a   Wu, Paul W ^b   Jussif, Jason ^b   Kasaian, Marion ^b   Carreno, Beatriz M ^b   Ling, Vincent ^b,c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b PFIZER INC   (United States)

^c Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIMER; INTERLEUKIN 2; LIGAND; MONOCLONAL ANTIBODY; PHOSPHATASE; POLYPEPTIDE; PROTEIN KINASE LCK; SERINE THREONINE PHOSPHATASE 2A; SINGLE CHAIN VARIABLE REGION FRAGMENT; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE PRODUCTION; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 2442552882     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.10.5948     Document Type: Article

References (64)

1. Alegre, M. L., K. A. Frauwirth, and C. B. Thompson. 2001. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1:220.
2. Chambers, C. A., M. S. Kuhns, J. G. Egen, and J. P. Allison. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19:565.
3. Carreno, B. M., F. Bennett, T. A. Chau, V. Ling, D. Luxenberg, J. Jussif, M. L. Baroja, and J. Madrenas. 2000. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J. Immunol. 165:1352.
4. Baroja, M. L., and J. Madrenas. 2003. Viewpoint: therapeutic implications of CTLA-4 compartmentalization. Am. J. Transplant. 3:919.
5. Rudd, C. E., and H. Schneider. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3:544.
6. Egen, J. G., M. S. Kuhns, and J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611.
7. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225.
8. Schwartz, J. C., X. Zhang, S. G. Nathenson, and S. C. Almo. 2002. Structural mechanisms of costimulation. Nat. Immunol. 3:427.
9. Zhang, X., J. C. Schwartz, S. C. Almo, and S. G. Nathenson. 2003. Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling. Proc. Natl. Acad. Sci. USA 100:2586.
10. Pawson, T., and P. Nash. 2003. Assembly of cell regulatory systems through protein interaction domains. Science 300:445.
11. Schwartz, J. C., X. Zhang, A. A. Fedorov, S. O. Nathenson, and S. C. Almo. 2001. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410:604.
12. Stamper, C. C., Y. Zhang, J. F. Tobin, D. V. Erbe, S. Ikemizu, S. J. Davis, M. L. Stahl, J. Seehra, W. S. Somers, and L. Mosyak. 2001. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410:608.
13. Hudson, P. J., and C. Souriau. 2003. Engineered antibodies. Nat. Med. 9:129.
14. Baeuerle, P. A., P. Kufer, and R. Lutterbuse. 2003. Bispecific antibodies for polyclonal T-cell engagement. Curr. Opin. Mol. Ther. 5:413.
15. Grosse-Hovest, L., I. Hartlapp, W. Marwan, G. Brem, H. G. Rammensee, and G. Jung. 2003. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol. 33:1334.
16. Holliger, P., T. Prospero, and G. Winter. 1993. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444.
17. Presta, L. 2003. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13:519.
18. Baroja, M. L., D. Luxenberg, T. Chau, V. Ling, C. A. Strathdee, B. M. Carreno, and J. Madrenas. 2000. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation. J. Immunol. 164:49.
19. Baroja, M. L., L. Vijayakrishnan, E. Bettelli, P. J. Darlington, T. A. Chau, V. Ling, M. Collins, B. M. Carreno, J. Madrenas, and V. K. Kuchroo. 2002. Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J. Immunol. 168:5070.
20. Darlington, P. J., M. L. Baroja, T. A. Chau, E. Siu, V. Ling, B. M. Carreno, and J. Madrenas. 2002. Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation. J. Exp. Med. 195:1337.
21. Griffin, M. D., D. K. Hong, P. O. Holman, K. M. Lee, M. J. Whitters, S. M. O'Herrin, F. Fallarino, M. Collins, D. M. Segal, T. F. Gajewski, et al. 2000. Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J. Immunol. 164:4433.
22. Connelly, R. J., M. S. Hayden, J. K. Scholler, T. T. Tsu, B. Dupont, J. A. Ledbetter, and S. B. Kanner. 1998. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes. Int. Immunol. 10:1863.
23. Chau, L. A., J. A. Bluestone, and J. Madrenas. 1998. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J. Exp. Med. 187:1699.
24. Shiratori, T., S. Miyatake, H. Ohno, C. Nakaseko, K. Isono, J. S. Bonifacino, and T. Saito. 1997. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 6:583.
25. Zhang, Y., and J. P. Allison. 1997. Interaction of CTLA4 with AP50, a clathrin-coated pit adaptor protein. Proc. Natl. Acad. Sci. USA 94:9273.
26. Cinek, T., A. Sadra, and J. B. Imboden. 2000. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4. J. Immunol. 164:5.
27. Nakaseko, C., S. Miyatake, T. Iida, S. Hara, R. Abe, H. Ohno, and T. Saito. 1999. Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement delivers an inhibitory signal through the membrane-proximal region in the absence of the tyrosine motif in the cytoplasmic tail. J. Exp. Med. 190:765.
28. Weiss, A., and J. Stobo. 1984. Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. J. Exp. Med. 160:1284.
29. Kappes, D. J., and S. Tonegawa. 1991. Surface expression of alternative forms of the TCR/CD3 complex. Proc. Natl. Acad. Sci. USA 88:10619.
30. Saito, T., and S. Yamasaki. 2003. Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol. Rev. 192:143.
31. Chuang, E., T. S. Fisher, R. W., Morgan, M. D. Robbins, J. M. Duerr, M. G. Vander Heiden, J. P. Gardner, J. E. Hambor, M. J. Neveu, and C. B. Thompson. 2000. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13:313.
32. Sontag, E. 2001. Protein phosphatase 2A: the Trojan horse of cellular signaling. Cell. Signal. 13:7.
33. Janssens, V., and J. Goris. 2001. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353:417.
34. Nebl, G., S. C. Meuer, and Y. Samstag. 1998. Cyclosporin A-resistant transactivation of the IL-2 promoter requires activity of okadaic acid-sensitive serine/threonine phosphatases. J. Immunol. 161:1803.
35. Richards, F. M., J. Milner, and S. Metcalfe. 1992. Inhibition of the serine/threonine protein phosphatases PP1 and PP2A in lymphocytes: effect on mRNA levels for interleukin-2, IL-2Rα, krox-24, p53, hsc70 and cyclophilin. Immunology 76:642.
36. Dounay, A. B., and C. J. Forsyth. 2002. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. Curr. Med. Chem. 9:1939.
37. Brizuela, L., E. T. Ulug, M. A. Jones, and S. A. Courtneidge. 1995. Induction of interleukin-2 transcription by the hamster polyomavirus middle T antigen: a role for Fyn in T cell signal transduction. Eur. J. Immunol. 25:385.
38. Damuni, Z., H. Xiong, and M. Li. 1994. Autophosphorylation-activated protein kinase inactivates the protein tyrosine phosphatase activity of protein phosphatase 2A. FEBS Lett. 352:311.
39. Glover, H. R., C. E. Brewster, and S. M. Dilworth. 1999. Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif. Oncogene 18:4364.
40. Pallas, D. C., L. K. Shahrik, B. L. Martin, S. Jaspers, T. B. Miller, D. L. Brautigan, and T. M. Roberts. 1990. Polyoma small and middle T antigens and SV40 small T antigen form stable complexes with protein phosphatase 2A. Cell 60:167.
41. Yokoyama, N., and W. T. Miller. 2001. Inhibition of Src by direct interaction with protein phosphatase 2A. FEBS Lett. 505:460.
42. Chen, J., S. Parsons, and D. L. Brautigan. 1994. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J. Biol. Chem. 269:7957.
43. Lee, K. M., E. Chuang, M. Griffin, R. Khattri, D. K. Hong, W. Zhang, D. Straus, L. E. Samelson, C. B. Thompson, and J. A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282:2263.
44. Mustelin, T., and K. Tasken. 2003. Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem. J. 371:15.
45. Lee, J. E., M. B. Cossoy, L. A. Chau, B. Singh, and J. Madrenas. 1997. Inactivation of lck and loss of TCR-mediated signaling upon persistent engagement with complexes of peptide: MHC molecules. J. Immunol. 159:61.
46. Gouy, H., P. Deterre, P. Debre, and G. Bismuth. 1994. Cell calcium signaling via GM1 cell surface gangliosides in the human Jurkat T cell line. J. Immunol. 152:3271.
47. Janes, P. W., S. C. Ley, and A. I. Magee. 1999. Aggregation of lipid rafts accompanies signaling via the T cell antigen receptor. J. Cell Biol. 147:447.
48. Kabouridis, P. S., J. Janzen, A. L. Magee, and S. C. Ley. 2000. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur. J. Immunol. 30:954.
49. Chikuma, S., J. B. Imboden, and J. A. Bluestone. 2003. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 197:129.
50. Yin, L., H. Schneider, and C. E. Rudd. 2003. Short cytoplasmic SDYMNM segment of CD28 is sufficient to convert CTLA-4 to a positive signaling receptor. J. Leukocyte Biol. 73:178.
51. Aivazian, D., and L. J. Stern. 2000. Phosphorylation of T cell receptor ζ is regulated by a lipid dependent folding transition. Nat. Struct. Biol. 7:1023.
52. Margulies, D. H. 2003. CD28, costimulator or agonist receptor? J. Exp. Med. 197:949.
53. Luhder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Muller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hunig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197:955.
54. Leff, P. 1995. The two-state model of receptor activation. Trends Pharmacol. Sci. 16:89.
55. Jordan, B. A., and L. A. Devi. 1999. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697.
56. Hermans, E. 2003. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol. Ther. 99:25.
57. Wu, Y., Y. Guo, A. Huang, P. Zheng, and Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med. 185:1327.
58. Zheng, P., Y. Wu, Y. Guo, C. Lee, and Y. Liu. 1998. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge. Proc. Natl. Acad. Sci. USA 95:6284.
59. Ito, D., K. Ogasawara, K. Iwabuchi, Y. Inuyama, and K. Onoe. 2000. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J. Immunol. 164:1230.
60. Boyle, J. S., J. L. Brady, and A. M. Lew. 1998. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 392:408.
61. Horspool, J. H., P. J. Perrin, J. B. Woodcock, J. H. Cox, C. L. King, C. H. June, D. M. Harlan, D. C. St. Louis, and K. P. Lee. 1998. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J. Immunol. 160:2706.
62. van Elsas, A., R. P. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J. P. Medema, W. W. Overwijk, N. P. Restifo, C. J. Melief, R. Offringa, and J. P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194:481.
63. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95:10067.
64. Hurwitz, A. A., B. A. Foster, E. D. Kwon, T. Truong, E. M. Choi, N. M. Greenberg, M. B. Burg, and J. P. Allison. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2444.